Low-risk MDS: non-transplant therapeutic approach

Cellular Therapy and Transplantation

article

Moshe Mittelman¹ 

[1] Tel Aviv Sourasky Medical Center;Tel Aviv University

关键词: Myelodysplastic syndrome;    low-risk;    diagnostics;    management;    targeted therapy;   

DOI  :  10.18620/ctt-1866-8836-2021-10-2-7-16

学科分类：肿瘤学

来源: Universitaetsklinikum Hamburg - Eppendorf / University Medical Center Hamburg - Eppendorf

【 摘 要 】

A significant progress has been made over the last couple of decades in understanding the biology and treatment of myelodysplastic syndromes. Based on several parameters (% blasts, cytogenteics, number of affected lineages) the patients are classified as having a lower-risk (LR) or higher risk disease. Here, we will focus on LR-MDS. The patients with LR-MDS are treated with RBC transfusions as needed, with or without erythroid stimulating agents. Luspatercept, an activin analogue, is a reasonable second line agent. Among the investigational agents in this field we can mention ruxodustat (a HIF inhibitor) and imetelstat, a telomerase inhibitor. Treatment of thrombocytopenia remain challenging and an open question.

【 授权许可】

CC BY